Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS12 | P56730 | 6/20 | 0.47 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.41 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 2/20 | 0.36 |
| ▸ | UBE2M | P61081 | 1/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139599 | 0.92 | PRSS12 (0.45) | PRSS12MCHR1NPC1UBE2MDCUN1D1 | |
| SCHEMBL4132750 | 0.84 | PRSS12 (0.50) | PRSS12TRPC3TRPC6MCHR1HSD11B1 | |
| SCHEMBL999164 | 0.78 | CMA1 (0.44) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL404207 | 0.78 | CMA1 (0.48) | PRSS12TRPC3TRPC6MAPK14MEN1 | |
| SCHEMBL10260371 | 0.77 | PRSS12 (0.43) | PRSS12TRPC3TRPC6MAPK14MEN1 | |
| SCHEMBL998620 | 0.77 | PRSS12 (0.48) | PRSS12MCHR1MAPK14SMN1; SMN2 | |
| SCHEMBL1000592 | 0.74 | SENP5 (0.50) | NPC1RAB9A | |
| SCHEMBL3220314 | 0.68 | PRSS12 (0.49) | PRSS12TRPC3TRPC6HSD11B1DRD2 | |
| SCHEMBL998624 | 0.67 | CMA1 (0.46) | SMN1; SMN2 | |
| SCHEMBL941582 | 0.67 | CMA1 (0.50) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | claimed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | claimed |
| US-20120259130-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | ANZALONE LUIGI (US) | 2012-10-11 | — | — | US | disclosed |
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | disclosed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | CMA1, PPA1, CPN1 | PRSS12 563/4885TRPC3 4652/4885TRPC6 3436/4885 |
| US-20120259130-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | CMA1, PPA1, CPN1 | PRSS12 563/4885TRPC3 4652/4885TRPC6 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.